REFERENCES
- Stern
RS, Divito SJ. Stevens-Johnson Syndrome and Toxic Epidermal
Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of
Progress but Still Much to Be Done. J Invest Dermatol 2017; 137:1004.
- Bastuji-Garin
S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic
epidermal necrolysis, Stevens-Johnson syndrome, and erythema
multiforme. Arch Dermatol 1993; 129:92.
- Roujeau
JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are
severity variants of the same disease which differs from erythema
multiforme. J Dermatol 1997; 24:726.
- Wetter
DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of
Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo
Clin Proc 2010; 85:131.
- Khalaf
D, Toema B, Dabbour N, Jehani F. Toxic epidermal necrolysis associated
with severe cytomegalovirus infection in a patient on regular
hemodialysis. Mediterr J Hematol Infect Dis 2011; 3: e2011004.
- Correia
O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic
epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.
Arch Dermatol 1993; 129:466.
- Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor
use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J
Allergy Clin Immunol 2011; 128:1266.
- Rzany
B, Hering O, Mockenhaupt M, et al. Histopathological and
epidemiological characteristics of patients with erythema exudativum
multiforme major, Stevens-Johnson syndrome and toxic epidermal
necrolysis. Br J Dermatol 1996; 135:6.
- Naegele
D, Sekula P, Paulmann M, Mockenhaupt M. Incidence of Stevens-Johnson
syndrome/toxic epidermal necrolysis: results of 10 years from the
German Registry. Pharmacoepidemiol Drug Saf 2017; 26(Supp 2):3.
- Sekula
P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of
a cohort of patients with Stevens-Johnson syndrome and toxic epidermal
necrolysis. J Invest Dermatol 2013; 133:1197.
- Mittmann
N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis
and Stevens-Johnson Syndrome in an HIV cohort: an observational,
retrospective case series study. Am J Clin Dermatol 2012; 13:49.
- Valeyrie-Allanore
L, Poulalhon N, Fagot JP, et al. Stevens-Johnson syndrome and toxic
epidermal necrolysis induced by amifostine during head and neck
radiotherapy. Radiother Oncol 2008; 87:300.
- Wolkenstein
P, Carrière V, Charue D, et al. A slow acetylator genotype is a risk
factor for sulphonamide-induced toxic epidermal necrolysis and
Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255.
- Slatore
CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin
North Am 2004; 24:477.
- Rotunda
A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions
associated with the use of human immunodeficiency virus medications.
Acta Derm Venereol 2003; 83:1.
- Theoharides
TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders.
N Engl J Med 2015; 373:163.
- Akin
C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed
diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099.
- Valent
P, Akin C, Arock M, et al. Definitions, criteria and global
classification of mast cell disorders with special reference to mast
cell activation syndromes: a consensus proposal. Int Arch Allergy
Immunol 2012; 157:215.